Slowdown or arrest of the cell cycle following DNA damage is a characteristic checkpoint response, which is a critical process that allows cells time to repair the DNA and avoid DNA replication or mitosis in the presence of damaged chromosomes. When DNA damage is excessive and repair incomplete, cells will activate the apoptotic cell death programme as a resultant outcome. This implies a link between checkpoint response and drug-induced cell death, and a strong correlation has indeed been demonstrated in the case of platinum-based drugs ([@bib46]). The tumour suppressor p53 has a central role in both DNA damage checkpoint response and apoptosis, but these functions generally require activation of p53, which then transactivates downstream genes for p53-dependent cellular effects. Activation of p53 by DNA damaging agents occurs following upregulation of discrete signal transduction pathways upstream and this is dependent on the type of DNA damage. Ionising radiation and doxorubicin, for instance, induce DNA strand breaks, which activate p53 via the ataxia telangiectasia mutated (ATM)-dependent pathway, whereas UV radiation and platinum-based cisplatin, on the other hand, induce in DNA the formation of cyclobutane pyrimidine dimers and intrastrand adducts, respectively, that activate p53 via the ataxia telangiectasia and Rad3-related (ATR)-dependent pathway ([@bib45]; [@bib44]). Irrespective of the type of DNA damage, a gene commonly transactivated by p53 following DNA damage by these and other agents is p21, and there is overwhelming evidence to support the seminal role of this transcriptional target in G1 checkpoint response ([@bib10]).

In essence, the DNA damage checkpoint is an integrated network of signal transduction pathways that allows cells to transfer information from the DNA lesion to the cell-cycle machinery via sensor, transducer and effector signalling proteins ([@bib21]). This sequence of events culminates in cyclin-dependent kinase (Cdk) inhibition, which attenuates cell-cycle progression. Inhibition of the binary Cdk4/cyclin D and Cdk2/cyclin E complexes is associated with activation of the G1-phase checkpoint to prevent G1/S transition, Cdk2/cyclin A with the S-phase checkpoint to slow progression through the S-phase, and Cdc2/cyclin A and Cdc2/cyclin B with the G2-phase checkpoint to prevent G2/M transition ([@bib39]; [@bib21]). Although these various Cdks can be inhibited by the Cip/Kip family members of inhibitors (p21, p27 and p57), p21 is the most critical for inhibiting G1-phase Cdk, primarily since p21 deletion alone can prevent G1-phase arrest ([@bib35]; [@bib39]), whereas other mechanisms exist to inhibit S- and G2-phase Cdks ([@bib35]).

Our recent studies have demonstrated that DNA damage by cisplatin and the platinum-based analogue diaminocyclohexane-diacetatao-dichloro-Pt(IV) (DAP) robustly inhibit G1-phase Cdk complexes in a p53/p21-dependent manner ([@bib18], [@bib17]). However, the nature of the inhibited Cdk complex induced by these Pt drugs and other antitumour agents remains uncertain. For instance, it is unclear whether recruitment of a single molecule of p21 is sufficient to inhibit Cdk ([@bib19]; [@bib2]) or if it is only a prerequisite for the assembly and catalytic activity of the Cdk complex, with multiple molecules needed to inhibit Cdk activity ([@bib52]; [@bib15]; [@bib28]; [@bib42]; [@bib8]). More importantly, there is also uncertainty whether other proteins are also recruited to modulate inhibition of the Cdk complex, although the possibility is strong since several proteins, such as c-Myc, PCNA, E2F4 and SET, have been reported to associate with the Cdk complex under basal conditions ([@bib20]; [@bib11]; [@bib26]; [@bib7]). Therefore, to better define inhibition of G1-phase Cdk complexes by platinum drugs, we have undertaken a proteomic analysis of the inhibited kinase complex. Our studies demonstrate that the size of the inhibited Cdk complex increases substantially, and this is ascribed to PCNA, which co-recruits with p21 and enhances the stability of the Cdk inhibitor within the Cdk complex.

Materials and methods
=====================

Chemicals
---------

DAP was synthesised and characterised as described previously ([@bib23]). Cisplatin, MTT and cycloheximide were purchased from Sigma (St Louis, MO, USA), and FBS obtained from BioWhittaker Inc. (Walkersville, MD, USA). LipofectAMINE 2000 (LF2000; cat. no. 11668-019) was purchased from Invitrogen (Carlsbad, CA, USA).

Cell culture and drug treatment
-------------------------------

Breast MCF-7 (in MEM), colon HCT-116 (McCoy\'s 5a), fibrosarcoma HT1080 (DMEM), ovarian A2780 (RPMI-1640) and ovarian OVCA-429 (MEM) tumour cells, all harbouring wild-type p53, were grown as sub-confluent monolayer cultures in medium supplemented with 10% FBS. For platinum treatment, cells (1--1.3 × 10^6^) were plated in 100-mm culture dishes and grown for at least 24 h when the cultures were replaced with fresh medium containing the drug. The cells were then further grown for up to 36 h and collected either for analysis of cell-cycle distribution by FACS or to prepare cell lysates, as previously described ([@bib27]).

Immunoblotting, immunoprecipitation and Cdk studies
---------------------------------------------------

Immunoblotting, immunoprecipitation and assays for Cdk activity were performed as previously described ([@bib27]). The antibodies used to immunoprecipitate Cdk4 (sc-601), Cdk2 (sc-163AC), cyclin D1 (sc-718), cyclin E (sc-248), Myc (sc-40), p21 (sc-397AC), and p27 (sc-528) and immunoblot cyclin D1 (sc-718), cyclin E (sc-247), PCNA (sc-56), Myc (sc-40) and p21 (sc-6246) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Other primary antibodies used to immunoblot Cdk4 (MS-299), Cdk2 (MS-617) and p27 (MS-256) were obtained from Neomarkers Inc. (Fremont, CA, USA). The primary antibody used to immunoblot *β*-actin (A5060) was purchased from Sigma. The horseradish peroxidase-conjugated secondary antibodies were purchased from Amersham Pharmacia (Piscataway, NJ, USA). The immunoblots were developed with ECL detection reagents (Amersham Pharmacia) with different lengths of exposures, and the protein bands on the developed films were quantified with the NIH Image software (version 1.62; Research Services Branch, NIH, Bethesda, MD, USA). The exposures that gave densitometry readings within a linear range were selected. Histone H1 (for Cdk2/cyclin E) or retinoblastoma (Rb) (for Cdk4/cyclin D1) was used as the substrate for assessing Cdk activity.

Gel filtration chromatography
-----------------------------

The procedure used in these studies has been previously reported by us ([@bib16]). Briefly, chromatography was conducted at 4 °C on a 40-ml Ultrogel AcA34 (LKB, Houston, TX, USA) column in an EB buffer, which consisted of 80 m[M]{.smallcaps} *β*-glycerophosphate, 20 m[M]{.smallcaps} EGTA, 200 m[M]{.smallcaps} NaCl, 15 m[M]{.smallcaps} MgCl~2~ and 1 m[M]{.smallcaps} dithiothreitol. In each gel filtration study, 0.5 ml of protein standards or crude cell lysates supplemented with 0.5 mg of purified GST (internal standard) was loaded onto the column, chromatographed and 1-ml fractions collected. A 40-*μ*l aliquot of fractions were separated by 12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS--PAGE), the gel-separated proteins transferred onto nitrocellulose membranes and stained with 0.1% Ponceau S in 5% acetic acid to reveal the elution profiles of GST and other cellular proteins. The membranes were then immunoblotted with anti-cyclin D1 or anti-cyclin E antibody. The cyclin D1 or E band was quantified by densitometry, and the band intensities normalised to the strongest signal, which was arbitrarily defined as 100.

Sucrose gradient analysis
-------------------------

Crude cell lysates from control or platinum drug-treated cells were layered on top of a 10--30% sucrose gradient and centrifuged for 16 h at 60 000 r.p.m. at 4 °C using an SW50.1 rotor in a Beckman L70 centrifuge (Fullerton, CA, USA). Twenty fractions of 180 *μ*l were collected from the top of the tube, proteins in collected fractions concentrated by TCA precipitation, and samples analysed by SDS--PAGE and immunoblotting.

Immunoprecipitation for proteomic analysis
------------------------------------------

Our previously reported procedure was followed ([@bib16]). Essentially, 15-ml crude cell lysates (∼10 mg protein per ml) from control or platinum drug-treated cells were first pre-absorbed for 4 h at 4 °C with 200 *μ*l of protein-A agarose (Sigma). To isolate the Cdk4/cyclin D complex, the cell lysates were then pre-cleared and incubated overnight at 4 °C with 25 *μ*g of polyclonal anti-cyclin D1 antibodies, or rabbit IgG (Sigma) as a control, that were conjugated covalently to 30 *μ*l of Affi-prep protein A beads (Bio-Rad, Hercules, CA, USA) by the dimethylpimelimidate-catalysed reaction ([@bib40]). The Cdk2/cyclin E complex was similarly isolated using 25 *μ*g of monoclonal anti-cyclin E antibody, using mouse IgG (Sigma) as a control, that were covalently linked to 30 *μ*l of protein-G sepharose (Amersham). After incubation, the beads were washed six times with buffer containing 0.5% NP-40, 150 m[M]{.smallcaps} NaCl, 2 m[M]{.smallcaps} EDTA, 2 m[M]{.smallcaps} EGTA, 5 m[M]{.smallcaps} sodium *β-*glycerophosphate, 10 m[M]{.smallcaps} NaF, 10% glycerol, 1 m[M]{.smallcaps} DTT, and 1 m[M]{.smallcaps} PMSF in 50 m[M]{.smallcaps} Tris--HCl (pH7.4) supplemented with the protease inhibitor cocktail (Roche, Indianapolis, IN, USA), and the precipitated proteins eluted with SDS--PAGE sample buffer and separated using a 12.5% SDS gel. Each gel slab was then fixed overnight in 40% ethanol/10% acetic acid and washed sequentially with 40% ethanol for 10 min and then deionised water for 15 min. The gel was next treated for 1 min with 0.02% sodium thiosulfate, rinsed twice for 1 min each with distilled water, submerged in 0.1% silver nitrate for 30 min, and then developed in 0.04% formalin in 3% sodium carbonate until a desired staining intensity was achieved. The reaction was stopped by the addition of 1/10 volume of 2.3 M citric acid to the developer and incubation of the gel in this solution for 15 min. The gel was then rinsed three times with distilled water and stored in distilled water at 4 °C ([@bib43]).

Polypeptide identification by mass spectrometry
-----------------------------------------------

Bands of interest on silver-stained gels were excised, de-stained with the Invitrogen Silver Quest kit, and washed five times with distilled water and then twice with 25 m[M]{.smallcaps} ammonium bicarbonate in 50% acetonitrile, as previously reported ([@bib16]). The bands were next digested (20 h) with trypsin (Promega, Madison, WI, USA) in 25 m[M]{.smallcaps} ammonium bicarbonate, and the resulting peptide fragments extracted twice with 0.01% trifluoroacetic acid/50% acetonitrile and concentrated to \<10 *μ*l by Speedvac (Thermo Savant, Holbrook, NY, USA). After purification by HPLC using C-18 Ziptips (Millipore, Bedford, MA, USA) and 2% acetonitrile/0.1% formic acid to wash and 70% acetonitrile/0.1% formic acid to elute the peptides, the acetonitrile was removed from the eluates by centrifugation in a Speedvac. Peptide mass fingerprinting (PMF) analysis was performed on a Voyager DE-STR linear MALDI TOF (Applied Biosystems, Framingham, MA, USA) in a positive ion and a reflected mode ([@bib47]), as described by us ([@bib25]). Dried droplet deposits of *α*-cyano-4-hydroxycinnamic acid were prepared by mixing the peptide solutions 1 : 1 with 10 mg ml^−1^ matrix in methanol. Database search utilised the Mascot (<http://www.matrixscience.com>) and Protein Prospector (<http://prospector.ucsf.edu>) websites. The PMF results were validated by peptide sequencing on an LCQ DecaXP electrospray quadrupole ion trap mass spectrometer (Thermo Finnigan, San Jose, CA, USA) coupled to an HP 1090 liquid chromatography system (Agilent, Palo Alto, CA, USA) ([@bib9]) and a 0.3-mm C-18 column (Vydac, Hesperia, CA, USA). The solvent system was composed of solution A (2% acetonitrile/0.01% trifluoroacetic acid) and solution B (98% acetonitrile/0.01% trifluoroacetic acid) that were applied as a 40-min linear gradient from 5% to 60% of B to elute the peptides. Data-dependent acquisition was conducted for 60 min by using two MS-MS steps after each MS1. Database search with the MS-MS data was performed with Sonar (Genomic Solutions, Ann Arbor, MI, USA).

Plasmids and transfection
-------------------------

Wild-type myc-p21 vector was prepared as described previously by us ([@bib16]). Briefly, p21 cDNA was amplified by PCR, digested with both *Eco*RI and *Xho*I enzymes and subcloned into pCMV-Myc vector (Clontech, Mountain View, CA, USA). Two mutant-p21 vectors p21^T145E^ (p21TE) and p21^T145E/S146D^ (p21ED) were prepared using the QuickChange II XL site-directed mutagenesis kit, following the manufacturer\'s instruction (Agilent, Santa Clara, CA, USA), to mimic phosphorylation at these sites that inhibits p21 binding to PCNA ([@bib41]; [@bib38]). The primers used were as follows: p21TE: 5′-GGTCGAAAACGGCGGCAGGAGAGCATGACAGATTTCTAC-3′ and 5′-GTAGAAATCTGTCATGCTCTCCTGCCGCCGTTTTCGACC-3′ p21ED: 5′-GGTCGAAAACGGCGGCAGGAGGACATGACAGATTTCTACCAC-3′ and 5′-GTGGTAGAAATCTGTCATGTCCTCCTGCCGCCGTTTTCGACC-3′. The wild-type pCMV-myc-PCNA vector was prepared in a similar manner, using the PCR primers 5′-CCGGAATTCGGATCCCGATGTTCGAGGCGCGCCTG-3′ and 5′-CCGCTCGAGCTAAGATCCTTCTTCATCCTCG-3′ for amplification. The mutant form of myc-PCNA vector (Y114A) was prepared by site-directed mutagenesis using the primers 5′-CCAAACCAGGAGAAAGTTTCAGACGCTGAAATGAAGTTGATGGATTTAGA-3′ and 5′-TCTAAATCCATCAACTTCATTTCAGCGTCTGAAACTTTCTCCTGGTTTGG-3′.

Empty, wild-type or mutant myc-p21 or myc-PCNA vector was transfected into tumour cells using LF2000, following the manufacturer\'s instructions. Briefly, cells were exposed to the transfection mixture containing LF2000 and plasmids for 5 h, washed and then replenished with normal media. Half-life of transfected p21 was determined by densitometric readings of bands in immunoblots of lysates from cells collected serially following exposure to 3 *μ*[M]{.smallcaps} cycloheximide to prevent further p21 synthesis. The half-life was determined from fitting the data to an exponential decay equation using the GraphPad Prism computer program (Graphpad Software, Inc., La Jolla, CA, USA).

*In vitro* binding of p21 to PCNA
---------------------------------

*In vitro* p21-PCNA binding was assessed as described previously ([@bib18]). Briefly, tumour cells were cultured in the presence or absence of the platinum drug for 24 h and crude lysates at 10 mg ml^−1^ protein were prepared from both control and drug-treated cells. To obtain boiled cell lysate, the drug-treated cell lysate was heated at 100 °C for 5 min and the soluble fraction was recovered after centrifugation at 13 000 *g* for 10 min. Depletion of p21 or p27 from the soluble fraction was achieved by immunoprecipitation with excess anti-p21 or anti-p27 antibodies. From the control cell lysate, Cdk2 complex was immunoprecipitated with anti-Cdk2 antibodies (1 *μ*g antibodies per 100 *μ*l cell lysate) immobilised onto agarose beads. After three washes, the beads were incubated with 5 *μ*l of untreated cell lysate (to provide endogeneous PCNA), 40 *μ*l of boiled drug-treated cell lysate (original, p21 or p27 pre-depleted) in a final volume of 50 *μ*l supplemented with the cell extraction buffer at room temperature for 30 min. After the beads were washed, they were separated by SDS--PAGE and immunoblotted for PCNA, p21 and p27 as described above.

Results
=======

DAP-induced cell-cycle arrest
-----------------------------

We have previously reported that DAP activates G1 checkpoint response ([@bib27]). To identify an optimal drug concentration for proteomic analysis of inhibited G1-phase Cdk and G1 arrest, A2780 tumour cells were exposed to a range of DAP concentrations for 36 h and cell-cycle distribution examined. [Figure 1A](#fig1){ref-type="fig"} demonstrates changes in cellular DNA histograms with increasing DAP concentrations, whereas [Figure 1B](#fig1){ref-type="fig"} summarises the distribution of cells in G1, S and G2/M phases as determined from these histograms. The figures reveal that cell numbers in G1 increase with increasing DAP concentration up to 0.8 *μ*[M]{.smallcaps}, and this is accompanied with a concomitant decrease in S and G2/M cells. Above this concentration, G1 cells decrease progressively, whereas cells in S and G2/M begin to increase. These results demonstrate selective activation of G1 checkpoint at low DAP concentrations (\<0.8 *μ*[M]{.smallcaps}), but combined G1, S and G2/M checkpoint activations at higher concentrations (\>0.8 *μ*[M]{.smallcaps}). On the basis of these studies, 0.6 *μ*[M]{.smallcaps} DAP was chosen for our proteomic investigations since this concentration ensured the absence of possible interference from any effects due to S and G2/M arrests, and also this concentration did not induce cell death during the 36-h time course of the study (data not shown). The lack of G2/M arrest is consistent with this concentration of DAP as having no effect on the kinase activity of Cdc2/cyclin A in G2 phase of the cell cycle ([@bib27]).

Increase in size of the inhibited Cdk4 and Cdk2 complexes
---------------------------------------------------------

To grossly assess whether inhibited G1-phase Cdk complexes bind proteins other than p21, an increase in the size of the inhibited complex following treatment of A2780 cells with 0.6 *μ*[M]{.smallcaps} was examined by gel filtration and gradient sedimentation analysis. The results from this investigation are shown in [Figure 2](#fig2){ref-type="fig"}.

When crude lysates from control or DAP-treated A2780 cells were fractionated on Ultrogel AcA34 gel column, and the fractions examined by immunoblots for cyclin D1 (as a marker for the Cdk4 complex) and cyclin E (for the Cdk2 complex), it was apparent that Cdk complexes from DAP-treated cells eluted earlier, suggesting an increase in the molecular size ([Figure 2A and C](#fig2){ref-type="fig"}). To assess kinase activities, Cdk was immunoprecipitated from fraction 26 of control and fraction 24 of DAP-treated cell lysate that represented peak levels of cyclin D1 ([Figure 2A](#fig2){ref-type="fig"}) or cyclin E ([Figure 2C](#fig2){ref-type="fig"}) and examined for Cdk4 or Cdk2 activities, respectively. Robust activities of both kinases were observed in control fraction 26, which equates to ∼140 kDa for the size of the complex, but the activities were reduced by over 95% in fraction 24 (∼290 kDa) arising from DAP-treated cells ([Figure 2B and D](#fig2){ref-type="fig"}). This demonstrates that inhibition of kinase activities following DAP treatment is associated with an increase in the size of the Cdk complex by ∼150 kDa. The increase in size was confirmed by sucrose gradient, which demonstrated a shift of the Cdk4 ([Figure 2E](#fig2){ref-type="fig"}) and Cdk2 complex ([Figure 2F](#fig2){ref-type="fig"}) in DAP-treated samples to a higher sucrose concentration.

Proteomic analysis identifies PCNA in inhibited G1-phase Cdk complexes
----------------------------------------------------------------------

On the basis of the data in [Figure 2](#fig2){ref-type="fig"}, it was reasonable to consider that the 150-kDa increase in size of the inhibited Cdk complex is likely due to recruitment of proteins other than p21 (21 kDa). Therefore, we performed large-scale cyclin D1 and E immunoprecipitates from DAP-treated A2780 tumour cells for proteomic analysis. The immunoprecipitates were resolved by SDS--PAGE and silver stained. Resolution of proteins in cyclin D1 and cyclin E immunoprecipitates from control (lane c) and DAP-treated cells (lane d) are shown in [Figure 3A and B](#fig3){ref-type="fig"}, respectively, together with IgG (lane a) and respective cyclin antibody controls (lane b). Six polypeptides of interest were visualised in cyclin D1 immunoprecipitates from DAP-treated cells. By mass spectrometry and database searches, they were identified as PCNA, cyclin D1, cyclin D2, Cdk4, Cdk2 and p21. The prominence of Cdk4, cyclin D1 and p21 is consistent with our reported observation that DAP upregulates p21 and increases the level of the Cdk4/cyclin D1 complex ([@bib16]). The presence of cyclin D2 and Cdk2 is not unexpected due to the reported cross-reactivity of D1 antibodies with D2 ([@bib31]) and association of cyclin D1 with Cdk2 ([@bib50]; [@bib33]). Proliferating cell nuclear antigen was only detected after DAP treatment. Similar results were seen with cyclin E immunoprecipitates ([Figure 3B](#fig3){ref-type="fig"}), where three polypeptide bands of interest in DAP-treated cell lysates were identified as cyclin E, PCNA and Cdk2. As with Cdk4/cyclin D1, the level of Cdk2/cyclin E complex is increased by DAP ([@bib16]), and this explains the prominence of Cdk2 and cyclin E bands in the blot. On the other hand, the p21 band in this blot was difficult to identify because of its poor resolution from a strongly staining non-specific overlapping band. Thus, DAP treatment induces recruitment of PCNA into the Cdk4/cyclin D and Cdk2/cyclin E complexes, and this was confirmed by gel co-elution of PCNA with Cdk4 or Cdk2 in immunoblots ([Figure 3C](#fig3){ref-type="fig"}).

Recruitment of PCNA into the Cdk4 and Cdk2 complex following DAP treatment of A2780 cells was validated by PCNA immunoblots of Cdk immunoprecipitates ([Figure 4A](#fig4){ref-type="fig"}). Proliferating cell nuclear antigen was detected in the Cdk4 complex by 6 h after DAP treatment, but became prominent at 18 h and remained so until the experiment was terminated at 36 h. Proliferating cell nuclear antigen was also prominently represented in the Cdk2 complex in the 18--36 h time range. It is noteworthy that although PCNA is abundantly present in A2780 cells, it is relatively undetectable in control active Cdk4 or Cdk2 complex ([Figure 4A](#fig4){ref-type="fig"}). To exclude the possibility that PCNA recruitment into the Cdk complex following DAP treatment was specific to only A2780 cells, four additional tumour models (HCT-116, HT1080, MCF-7 and OVCA-429) were also examined for PCNA binding to the Cdk2 complex. These tumour models when exposed to DAP at concentrations inducing selective G1 arrest ([@bib18]) (see figure legend for details) similarly demonstrated recruitment of p21 ([Figure 4B](#fig4){ref-type="fig"}) and PCNA ([Figure 4C](#fig4){ref-type="fig"}) into the Cdk complex, and indicated that this PCNA recruitment, like p21, is a general response to DAP treatment and is present in the complex at the time when Cdk activity is inhibited ([Figure 4D](#fig4){ref-type="fig"}). Similar results were also observed with cisplatin in the representative A2780 model using a concentration of 1 *μ*[M]{.smallcaps} that was equitoxic with DAP (data not shown), and this indicates that the recruitment of PCNA is not platinum drug specific.

Recruitment of PCNA into the Cdk complex is p21 dependent and occurs as a trimer
--------------------------------------------------------------------------------

Results in [Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"} demonstrate that PCNA is present in abundance in cells, but only becomes bound to the G1-phase Cdk complex in parallel with p21 binding and correlates with inhibition of Cdk/cyclin activity. Since PCNA binds to not only p21, but also Cdk and cyclin ([@bib32]), the basis for recruitment of PCNA into the Cdk/cyclin complex is uncertain. However, levels of PCNA in immunoprecipitates of Cdk4 or Cdk2 from control A2780 tumour cells were either low or undetectable ([Figure 4A](#fig4){ref-type="fig"}), and this implicates p21 as being responsible for recruitment of PCNA into the inhibited G1-phase Cdk/cyclin complex, either via a direct physical interaction with p21 or a change in Cdk or cyclin conformation as a result of binding of p21 to Cdk/cyclin. To provide definitive evidence for the underlying basis for PCNA recruitment, and the consequence of this on Cdk/cyclin activities, a series of investigations were undertaken in control and DAP-treated A2780 tumour cells.

The study to investigate a direct or indirect effect of p21 on PCNA recruitment into the Cdk complex involved reconstitution of excess Cdk2 immunoprecipitated (using antibodies bound to agarose beads) from control cells with control cell lysates (as a source of PCNA) and either boiled cell lysate from DAP-treated cells that removed PCNA (but not p21 and p27) or this boiled lysate from which p21 or p27 was first immunodepleted. After 30-min incubation at room temperature, the agarose beads were washed and the bound proteins resolved by SDS--PAGE and immunoblotted. The results in [Figure 5A](#fig5){ref-type="fig"} demonstrate that PCNA was minimally bound to Cdk2 in control incubations (lanes 1 and 2) or in the presence of p27 alone (lane 4), but the binding increased substantially only in the presence of p21 (lanes 3 and 5). Thus, the binding of PCNA was likely due to a direct protein--protein interaction with p21, and not a consequence of Cdk inhibition since the Cdk inhibitor p27 that lacks the PCNA-binding domain had no effect. To corroborate this, phosphomimetic mutants p21TE and p21ED were created by respectively mutagenising the T145 and T145/S146 sites of myc-tagged wild-type p21 (p21wt) and transfected into A2780 tumour cells. Failure of these mutants to bind to PCNA has been previously reported ([@bib41]; [@bib38]), and this was confirmed in myc and PCNA immunoblots of myc immunoprecipitates ([Figure 5B](#fig5){ref-type="fig"}, lanes 5 and 6 *vs* lane 4). Similarly, Cdk2 immunoprecipitation followed by immunoblot analysis demonstrated that both wild-type and mutant p21 bound to Cdk2, but co-binding of PCNA to the Cdk complex occurred only in the presence of p21wt ([Figure 5C](#fig5){ref-type="fig"}). However, p21 mutants, like wild-type p21, inhibit Cdk, as is evident by diminished *in vitro* Cdk activity against the substrate histone H1 ([Figure 5C](#fig5){ref-type="fig"}) or by an endogeneous cellular decrease in hyperphosphorylated form (upper band) and a concomitant increase in hypophosphorylated form (lower band) of the Rb substrate ([Figure 5D](#fig5){ref-type="fig"}). This consolidates the conclusion that PCNA is not recruited as a result of Cdk inhibition.

These results indicate that PCNA and p21 interact directly and are co-recruited into the Cdk complex, and that the presence of PCNA is not required for p21-dependent inhibition of Cdk. From a proteomic consideration, however, recruitment of a single molecule each of PCNA and p21 to form a tetrameric complex still does not fully explain the ∼150-kDa difference between the molecular size of the active and inhibited Cdk complex. Since PCNA functions as a DNA processivity factor in a homotrimeric form ([@bib32]), it was possible that PCNA may also be bound to p21 in the Cdk complex as a homotrimer. This possibility was investigated by studies involving co-transfection of myc-p21wt with either myc-tagged wild-type PCNA (wt-PCNA) or a mutant myc-PCNA^Y114A^ that cannot form the homotrimer ([@bib22]). Co-transfections in A2780 cells resulted in good expression of p21 and PCNA, as seen in immunoblots of cell lysates ([Figure 6A](#fig6){ref-type="fig"}, upper panel). When these lysates were immunoprecipitated with Cdk4 (middle panel) or Cdk2 antibodies (lower panel), PCNA was co-immunoprecipitated only when wt-PCNA was expressed and in conjunction with co-expression of p21wt. Essentially similar results were obtained when cells transfected with either wt-PCNA or PCNA^Y114A^ were exposed to DAP to increase endogeneous expression of p21 as a result of DNA damage response ([Figure 6B](#fig6){ref-type="fig"}). These results indicate that PCNA is co-recruited with p21 into the Cdk complex primarily as a homotrimer.

Endogeneous PCNA stabilises p21 in the Cdk complex
--------------------------------------------------

The presence of PCNA as a homotrimer in the quartenary Cdk complex was a seminal observation but did not explain the underlying purpose of PCNA recruitment. However, the results in [Figure 6B](#fig6){ref-type="fig"} provided a clue that exogeneous expression of wt-PCNA may stabilise endogeneous basal p21 compared with empty vector control (lane 3 *vs* 1) or mutant PCNA^Y114A^ (lane 3 *vs* 5). This possibility was examined by measuring the half-life of wild-type and mutant p21 transfected in A2780 cells. The results indicate that the p21TE and p21ED mutants decay about two-fold faster than p21wt (*t*~1/2~: ∼0.5 *vs* 1.2 h) when examined in crude cell lysates ([Figure 7A](#fig7){ref-type="fig"}). Similar results were seen for p21 bound to the Cdk4 complex (*t*~1/2~: ∼0.7--0.8 for mutants *vs* 1.2 h for wild-type) when Cdk4 immunoprecipitates were examined ([Figure 7B](#fig7){ref-type="fig"}). In consonance, the stability of p21wt was greatest in Cdk2 immunoprecipitates (*t*~1/2~: 2.6 h), followed by p21ED (*t*~1/2~: 1.0 h) and then p21TE (*t*~1/2~: 0.5 h) ([Figure 7C](#fig7){ref-type="fig"}). These results strongly indicate that PCNA stabilises p21.

Discussion
==========

Cancer is caused by deregulation of the cell cycle, enabling tumour cells to proliferate without limits. However, many cancers retain the G1 checkpoint and respond to DNA damage by inducing/activating the tumour suppressor p53, which then transactivates a number of downstream gene targets, including p21. In concordance with this understanding, our studies demonstrate that exposure of tumour cells to the platinum complex DAP results in G1 arrest, which is directly due to inhibition of G1-phase Cdk4/cyclin D and Cdk2/cyclin E activities by p21. However, to our knowledge, our proteomic investigation is the first to demonstrate that the inhibition of G1-phase Cdk following DNA damage is associated with co-recruitment of p21 and trimeric PCNA to form a quaternary Cdk/cyclin/p21/PCNA complex. Moreover, our study reveals that PCNA does not inhibit Cdk activity but contributes indirectly by stabilising p21, the principle inhibitor of G1-phase Cdks, following DNA damage.

Levels of p21 are usually low in tumour cells to permit the unabated proliferation, but the levels increase following DNA damage to inhibit Cdk activity and induce cell-cycle arrest, as we have noted in this and other studies with platinum drugs cisplatin and DAP ([@bib27]; [@bib17]). This increase in p21 is slow as it is mediated via transcriptional activation, and increases in p21 protein levels in cells or complexed to Cdk4/cyclin D and CDk2/cyclin E first become apparent at 6 h, but do not become prominent until 18 h after initiating drug exposure ([@bib18]). In the present study, we have demonstrated that this binding of p21 to Cdk/cyclin is associated with co-recruitment of PCNA, which interestingly also appears in the complex at 6 h and becomes prominent at 18 h, and this is consistent with our finding that PCNA is co-recruited in a p21-dependent manner. It is noteworthy that PCNA is recruited into the Cdk4 complex before the Cdk2 complex, but this again is consistent with parallel recruitment of induced p21 first into the Cdk4 complex ([@bib14]; [@bib18]). Our studies, however, do not indicate whether p21 and PCNA recruitment into the Cdk/cyclin complex occurs sequentially or whether p21 binds first to PCNA. Given that p21 can interact directly with PCNA in the absence of Cdk/cyclin ([@bib48]; [@bib29]), it is plausible that p21 and PCNA bind first before being recruited into G1-phase Cdk/cyclin to form the quaternary Cdk complex. On the other hand, our data support several reports that both wild-type p21 in the absence of PCNA ([@bib14]) and engineered p21 to prevent PCNA binding ([@bib37]; [@bib4]; [@bib38]) still interact with Cdk/cyclin complex to inhibit kinase activity, and so the possibility that p21 recruitment may occur before PCNA into the inhibited complex cannot be excluded. Thus, further studies are needed to resolve the sequence of interaction between the Cdk/cyclin, p21 and PCNA to form the quaternary complex.

The quaternary Cdk/cyclin/p21/PCNA complex has previously been described in control non-transformed human cells, such as lung and foreskin fibroblasts, but not in transformed cells where p21 and PCNA become excluded from the complex ([@bib50], [@bib51]; [@bib53]). In our studies in control A2780 ovarian tumour cells, the most consistent interpretation of gel chromatography elution profiles and immunoprecipitation and immunoblot data is that the Cdk complex is present in a range of molecular sizes, which may well include the quaternary complex, but most likely at low levels. However, it appears from molecular size consideration that the ∼140 kDa of the active Cdk complex in fraction 26 may not be attributable to the simple binary interaction between Cdk (∼31--32 kDa) and the cognitive cyclin D (∼33--34 kDa) or cyclin E (∼50 kDa). In this regard, similar-sized 120 and 160 kDa Cdk complexes in control human T47D breast tumour cells and a 150 kDa complex in 293 embryonic kidney cells have been reported to contain p21 ([@bib34]; [@bib36]). Therefore, it is tempting to speculate the presence of p21 as a component of the ∼140 kDa complex, but this is not supported by the finding in the present investigation that Cdk4 and Cdk2 complexes immunoprecipitated from control A2780 tumour cells contained little or no detectable p21 or PCNA ([Figure 4](#fig4){ref-type="fig"}). Indeed, p21 is not required for the formation of the binary Cdk/cyclin complex, as has been demonstrated in p21-deficient cells ([@bib7]). Thus, the presence of p21 at a significant level in the active ∼140 kDa kinase complex from tumour cells in our study appears unlikely, nor necessary, but this does not exclude the possible presence of another protein within the active Cdk complex that evaded detection.

Our proteomic analysis revealed the presence of only Cdk, cyclin, p21 and PCNA in the inhibited G1-phase Cdk complex following DNA damage with DAP. This is surprising and contrary to expectations since PCNA can bind to a number of proteins, such as Topo I, Fen-1 and CAF-1 ([@bib32]). However, it is highly plausible that binding with p21 prevents PCNA from interacting with other proteins in a mutually exclusive manner, as has been noted with DNA replication proteins Fen-1, RF-C and Pol-*δ* ([@bib48]; [@bib5]). Moreover, the 150-kDa difference in the molecular size among the smaller, active and larger, inhibited Cdk complex following DNA damage can be explained in part by the presence of PCNA as a homotrimer in the present investigation. Although the binding of p21 to trimeric PCNA has been proposed previously, but under basal conditions or in cell-free systems using purified proteins, there is much disagreement in the literature over the stoichiometry. Some reports have indicated that only one molecule of p21 is bound to trimeric PCNA independent of Cdk/cyclin ([@bib53]; [@bib49]; [@bib48]), whereas others have suggested multiple p21 molecules associate with trimeric PCNA, with stoichiometry of 2--3 : 1 ([@bib12]; [@bib29]; [@bib54]). The crystal structures of PCNA bound to p21 peptides have been described, but again a definitive understanding for the stoichiometry is lacking. [@bib13] investigated binary interactions between p21 and PCNA and proposed three peptides bound to trimeric PCNA within the crystal structure. On the other hand, [@bib24] have proposed a model for the quaternary Cdk/cyclin/p21/PCNA structure that only requires a single p21 molecule functioning as an adaptor protein between cyclin and a single PCNA of the homotrimer. This model, however, does not preclude the possibility of two additional molecules of p21 bound to the other two molecules of PCNA in the trimeric structure. Indeed, and in the absence of any other proteins associated with PCNA in our studies, the increase in the molecular size of the inhibited Cdk complex by ∼150 kDa can be best described by recruitment of three molecules of p21 (molecular weight (MW) ∼21 kDa each) bound to trimeric PCNA (MW ∼84--86 kDa total).

Irrespective of the stoichiometry of proteins within the quaternary structure of the inhibited Cdk complex, our data in A2780 tumour cells reveal that PCNA is not essential for p21 to inhibit Cdk activity (see [Figure 5C](#fig5){ref-type="fig"}), which is consistent with reports using cell-free systems ([@bib2]). This, therefore, raises a major question as regards the function of PCNA within the Cdk complex. Since the cellular level of p21 is reduced following its mutation at specific amino-acid sites that prevent p21 binding to PCNA, it has been proposed that PCNA protects p21 from proteosomal degradation ([@bib3]). In contrast, others have reported that PCNA binding promotes p21 degradation ([@bib30]; [@bib1]). Moreover, these reports did not examine the stability of p21 within the Cdk complex, and to the best of our knowledge such information has also not been reported by others. Our study, on the other hand, provides unequivocal evidence that PCNA stabilises p21 not only in tumour cells, but specifically within Cdk4 and Cdk2 complexes, which likely explains the robustness of Cdk inhibition and G1 arrest by p21. This may also explain the reported correlation between robust checkpoint response and drug sensitivity with platinum antitumour drugs ([@bib46]) and the reported abolishment of apoptosis in the presence of p21PCNA that cannot bind to PCNA ([@bib6]).

In summary, we have demonstrated that DNA damage by Pt-based antitumour agents induces p21-dependent inhibition of G1-phase Cdk4/cyclin D and Cdk2/cyclin E activity that is associated with an ∼150 kDa increase in the molecular size of the Cdk complex. This large shift in size is due to recruitment of trimeric PCNA, likely bound to three molecules of p21 to form the Cdk/cyclin/p21/PCNA quaternary complex as a consequence of DNA damage response. Our data indicate that PCNA is not essential for inhibiting Cdk activity, but is required to stabilise and, thereby, prolong the inhibitory activity of p21 within the Cdk complex.
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![**The effect of DAP on cell-cycle kinetics.** A2780 cells were incubated with DAP (0--6.4 *μ*[M]{.smallcaps}) for 36 h and then analysed for cell-cycle distribution by FACS. DNA content histograms (**A**) and quantified percentages of cells distributed in different phases of the cell cycle (**B**) are shown.](bjc2013613f1){#fig1}

![**Increase in the molecular size of the inhibited Cdk4 and Cdk2 complexes in DAP-treated cells.** Crude cell lysates prepared from control or 24-h DAP-treated A2780 cells were fractionated according to size by gel filtration, proteins in fractions (Fr) visualised by immunoblotting, the bands of interest quantified by densitometry and normalised (**A**--**D**). The size fractionation profile of cyclin D and molecular markers was established (**A**) and fractions with peak cyclin D levels (fraction 26 of control and fraction 24 after DAP treatment) selected to prepare Cdk4 immunoprecipitates for estimation of kinase activity using Rb as the substrate for ^32^P-phosphorylation (**B**). Similar approaches were taken for cyclin E distribution (**C**) and estimation of Cdk2 kinase activity against histone H1 as the substrate (**D**). Crude cell lysates were also subjected to 10--30% sucrose gradient sedimentation for size distribution of cyclin D (**E**) and cyclin E (**F**) complex.](bjc2013613f2){#fig2}

![**DAP treatment induces recruitment of PCNA into Cdk4 and Cdk2 complexes.** Covalently linked anti-cyclin D or control rabbit IgG was used for large-scale preparation of immunoprecipitates from untreated or DAP-treated A2780 cell lysates, and the eluted proteins from antibody beads were resolved by SDS--PAGE and visualised by silver staining (**A**). Protein bands seen to increase in intensity following DAP treatment were analysed by mass spectrometry, and their identity is indicated. Cyclin E immunoprecipitates were prepared and analysed in an identical manner (**B**). Lane a, control anti-cyclin D or E antibody beads; Lane b, rabbit (**A**) or mouse (**B**) IgG immunoprecipitates from control cell lysate; Lane c, anti-cyclin D or E immunoprecipitates from control cell lysate; Lane d, anti-cyclin D or E immunoprecipitates from DAP-treated cell lysate. The single asterisk (\*) indicates cross-reactive polypeptides that were immunoprecipitated by the anti-cyclin D or anti-cyclin E antibodies, and the double asterisk (\*\*) is associated with non-specific polypeptides that bound to rabbit or mouse IgG. The \# symbol indicates light chain and cleaved heavy chain of the precipitating antibody. The crude cell lysates from control or 24-h DAP-treated cells were also fractionated by gel filtration, exactly as indicated in [Figure 2](#fig2){ref-type="fig"}, and the fractions immunoprecipitated (IP) with cyclin D or E antibodies and immunoblotted for Cdk4, Cdk2 and PCNA (**C**).](bjc2013613f3){#fig3}

![**Recruitment of PCNA into Cdk4 and Cdk2 complexes correlates with DAP-induced inhibition of Cdk4 and Cdk2 activities.** Crude cell lysates of A2780 cells treated with DAP for the indicated length of time were immunoprecipitated with either anti-Cdk4 or anti-Cdk2 antibody, and the lysates and immunoprecipitates (IP) immunoblotted for PCNA (**A**). Additional cell lines exposed to DAP (MCF-7, 0.4 *μ*[M]{.smallcaps}; HCT-116, 2 *μ*[M]{.smallcaps}; OVCA-429, 2 *μ*[M]{.smallcaps}; HT1080, 4 *μ*[M]{.smallcaps}) for 24 h were similarly processed to isolate Cdk2 immunoprecipitates, which were then either separated by SDS--PAGE and immunoblotted for p21 and PCNA or assessed for kinase activity by ^32^P-phosphorylation of histone H1. The band signals from p21 (**B**), PCNA (**C**) and ^32^P-cpm (counts per minute) (**D**) are shown normalised for band intensity associated with Cdk2 from the immunoblot.](bjc2013613f4){#fig4}

![**The recruitment of PCNA by Cdk complex is p21 dependent.** Cdk2 immunoprecipitate (using antibodies bound to agarose beads) from control A2780 cell lysate, control lysate (as a source for PCNA), and boiled, p21- or p27-immunodepleted lysate from A2780 cells previously exposed to 0.6 *μ*[M]{.smallcaps} DAP for 24 h were incubated for 30 min at room temperature, the beads washed and bound proteins identified by immunoblot (IB) analysis (**A**). In a separate study, myc immunoprecipitates from lysates of A2780 cells transfected 24 h earlier with wild type (wt) or mutant (TE or ED) myc-p21 were prepared and the bound proteins then visulaised by SDS--PAGE/immunoblot procedure (**B**). Alternatively, lysates from A2780 cells, transfected with myc-p21 (wt or ED) 24 h earlier, were used to immunoprecipitate (IP) Cdk2 complex, which was then either separated by SDS--PAGE and immunoblotted with the indicated antibodies or used for estimation of kinase activity using histone H1 (**C**). The effect of transfected myc-p21 (wt, TE or ED) on intracellular Cdk activity in A2780 cells was assessed by monitoroing the mobility shift of Rb from a hyper- to a hypo-phosphorylated state in immunoblots (**D**).](bjc2013613f5){#fig5}

![**PCNA binds to Cdk complex as a trimer.** A2780 cells were transfected for 5 h with wild-type (wt) myc-p21, myc-PCNA (wt-PCNA) and/or myc-PCNA engineered to prevent its homotrimerisation (mutant-PCNA), and lysates prepared 19 h later (**A**). Alternatively, cells transfected with wt-PCNA or mutant-PCNA for 5 h were exposed to DAP 7 h later to upregulate p21, and lysates prepared after a further 24 h (**B**). Cdk4 and Cdk2 immunoprecipitates (IP) from lysates were prepared, resolved by SDS--PAGE and immunoblotted with the indicated antibodies.](bjc2013613f6){#fig6}

![**Inhibiting PCNA binding decreases the half-life of p21 in A2780 cells.** A2780 cells were transfected with equal amounts of wild-type (p21wt) or mutant (p21TE and p21ED) p21, and 24 h later the cells were incubated with 3 *μ*[M]{.smallcaps} of cyclohexmide (CHX) for up to 4 h. Cells were collected at timed intervals after adding CHX (set as time zero), and cell lysates (**A**) or immunoprecipitates (IP) of Cdk4 (**B**) and Cdk2 (**C**) from lysates prepared, resolved by SDS--PAGE and immunoblotted with the indicated antibodies. The myc-p21, Cdk and *β*-actin signals in the immunoblots were quantified by densitometry, the ratios of p21/Cdk or p21/*β*-actin normalised to the level at time zero and plotted. The half-life of myc-p21 was calculated by a computer program.](bjc2013613f7){#fig7}
